www.ohri.ca
Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Prospects
Reprogramming tumour cells to enhance responsiveness to targeted immunotherapy by engineering the combination of selective antibody-drug conjugates with anti-cancer virotherapy agents. (Drs. Z. Taha & M. Crupi)